An interventional study of Supira System in Heart Diseases, Coronary Artery Disease (CAD) and Heart Failure, sponsored by Supira Medical. Active, not recruiting at 2 sites in Brazil. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Supira Medical · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Heart Diseases with a site in Brazil — 11 open to participants now, 13 under way, 3 of them phase 3. Heart Diseases · Brazil.
Among the 48 studies in Heart Diseases with a site in Brazil, this one is the 33rd largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2023, is one of 21 with no phase, reaches primary completion later than 2 of the 12 other live ones, and was the 38th registered.
2,135 studies on the registry are indexed under Heart Diseases; 251 are open to participants now.
Browse Heart Diseases studies →11 of the 48 studies in Heart Diseases with a site in Brazil are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Brazil, United States, Canada and 6 more countries
Ages 6+
Eli Lilly and Company · Sites in Brazil, Argentina, Australia and 35 more countries
Ages 50+
Lexeo Therapeutics · Sites in Brazil, United States, Canada and 5 more countries
Ages 6+
Abbott Medical Devices · Sites in Brazil, France, Germany and 6 more countries
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in Brazil, United States, Argentina and 21 more countries
Ages 18–75
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 182 Heart Diseases studies recruiting now, 129 (71%) set no upper age limit and 21 (12%) stop at 75 or younger; 33 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 16 · Phase 4 5
First in 2004; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 71 is below the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 274 across the 44 interventional studies, 297 across the 4 observational. Of the 28 that completed or were terminated, 13 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 48 have an industry lead sponsor. The 10 most frequent:
Supira Medical is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Supira Medical has 2 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Diseases with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217392Abbott Medical DevicesLeft Bundle Branch Area Pacing (LBBAP) PMCF Study | 2027-04-30 |
| NCT06865482Lexeo TherapeuticsClinical Course Of Disease In Participants With FA-CM | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies in Heart Diseases with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing high-risk percutaneous interventions (HRPCI).
The Feasibility Study SA is a prospective, single-arm, interventional multi-center study enrolling up to 100 treated subjects.
The Supira Catheter is a single-use percutaneous expandable blood pump designed to unload the left ventricle by actively transporting blood from the left ventricle into the aorta.
The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option
To be eligible, subjects must meet ALL of the following inclusion criteria:
To be eligible, subjects must NOT meet ANY of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing non-emergent, high-risk percutaneous coronary interventions.
Device: Supira System
The Supira System is a temporary (≤ 4 hours) ventricular support device indicated for use during elective or urgent high-risk percutaneous coronary interventions (HRPCI) performed in hemodynamically stable patients with severe coronary artery disease when a heart team has determined HRPCI is the appropriate therapeutic option.
Primary Feasibility Endpoint: Successful initiation and maintenance of hemodynamic support without sustained hypotension throughout the index procedure.
Sustained hypotension is defined as sustained mean arterial pressure (MAP) \< 60mmHg requiring (1) more than one administration of inotropes/vasopressors within 5 minutes, OR (2) continuous infusion of inotropic/pressor medications, OR 3) alternative mechanical circulatory support, to restore hemodynamics.
Time frame: From device delivery through device removal (up to 4 hours).
Primary Safety Endpoint: Rate of composite major device-related adverse events (MDRAEs), from device delivery through device removal.
MDRAEs related to the device.
Time frame: From device delivery through device removal (up to 4 hours).
Rate of Technical Success.
Completion of the entire Supira System procedure, including delivery, operation without device malfunction, and successful retrieval of the catheter.
Time frame: From device delivery through device removal (up to 4 hours).
Rate of Procedural Success
Rate of technical success without procedural serious adverse events (SAEs).
Time frame: From device delivery through device removal (up to 4 hours).
Rate of composite MDRAEs from device removal through hospital discharge or 72 hours post-procedure, whichever comes first.
MDRAEs related to the study device.
Time frame: From device removal through hospital discharge or 72 hours post-procedure, whichever occurs first.
Rate of composite MDRAE from hospital discharge or 72 hours post-procedure (whichever occurs first) through 30 days post device removal.
Major adverse events related to the study device.
Time frame: From hospital discharge or 72 hours post-procedure (whichever occurs first)
Rate of composite MDRAE from 30 days to 90 days post device removal (for subjects enrolled and treated after the first 30 subjects).
Major adverse events related to the device.
Time frame: From 30 days to 90 days post device removal.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Apr 2025, 19 months.
Of 73 industry-sponsored interventional studies with no phase under Heart Diseases, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's 19 months is below that.
Counting every sponsor, half of 336 studies reached it within 25 months; a quarter within 10 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Supira Medical